[1] B. F, F. J, S. I, S. RL, T. LA, J. A, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians 68(6) (2018) 394-424.
[2] T. LA, B. F, S. RL, F. J, L.-T. J, J. A, Global cancer statistics, 2012, CA: a cancer journal for clinicians 65(2) (2015) 87-108.
[3] T. LA, S. RL, J. A, Lung Cancer Statistics, Advances in experimental medicine and biology 893 (2016) 1-19.
[4] B. A, P. A, M. E, R. T, N. DM, C. AR, A. A, Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention, Cancer treatment and research 159 (2014) 401-26.
[5] B. A, F. G, A. A, N. DM, A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis, Journal of the National Cancer Institute 106(8) (2014) dju200.
[6] B. FR, C. M, H. T, The tumor microenvironment at a glance, Journal of cell science 125 (2012) 5591-6.
[7] S. RD, O. LJ, S. MJ, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science (New York, N.Y.) 331(6024) (2011) 1565-70.
[8] D. M, M. C, S. LM, C. AF, J. T, Expression of tumour-specific antigens underlies cancer immunoediting, Nature 482(7385) (2012) 405-9.
[9] N. DM, D.L.B. A, V. N, M. L, A. A, Inflammation, inflammatory cells and angiogenesis: decisions and indecisions, Cancer metastasis reviews 27(1) (2008) 31-40.
[10] C. LM, W. Z, Inflammation and cancer, Nature 420(6917) (2002) 860-7.
[11] P. F, V. MA, B. D, N. A, M. D, S. A, D.S. C, N. L, D.P. M, A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships, Blood 114(4) (2009) 901-14.
[12] X. H, R. CP, H. J, Z. C, W. H, W. AA, A. R, G. P, S. MA, S. XS, C. PJ, C. M, M. JR, S. D, L. A, J. Y, M. LY, C. A, B. PE, Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma, Cancer immunology research 8(4) (2020) 436-450.
[13] M. JD, P. M, W. C, K. TT, M. MR, V. C, T. K, P. P, M. F, P. C, I. G, T. S, G. N, S. T, W. ME, M. VA, Q. S, N. J, L. RM, K. M, S. MD, S. T, K. K, C. H, Dexamethasone Increases Cisplatin-Loaded Nanocarrier Delivery and Efficacy in Metastatic Breast Cancer by Normalizing the Tumor Microenvironment, ACS nano 13(6) (2019) 6396-6408.
[14] X. R, L. Y, N. AG, R. RA, Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis, Immunological reviews 222 (2008) 117-28.
[15] D. Z, W. J, X. B, J. Z, W. G, Z. J, P. M, G. Y, W. Z, Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma, BioMed research international 2019 (2019) 2408348.
[16] N. J, W. Y, Q. F, L. X, Y. S, L. S, F. J, Z. Y, Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia, Frontiers in oncology 9 (2019) 1509.
[17] H. D, W. RA, The hallmarks of cancer, Cell 100(1) (2000) 57-70.
[18] H. D, C. LM, Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer cell 21(3) (2012) 309-22.
[19] K. J, B. SE, Y. GH, K. KH, H. ML, M. HE, H. JJ, L. SM, M. DK, M. MW, H. AM, Neutrophils dominate the immune cell composition in non-small cell lung cancer, Nature communications 8 (2017) 14381.
[20] B. GA, T. A, P. SS, W. J, W. A, O. C, E. K, S. T, G. F, S. W, F. L, S. R, Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma, PloS one 10(9) (2015) e0139073.
[21] Q. DF, J. JA, Microenvironmental regulation of tumor progression and metastasis, Nature medicine 19(11) (2013) 1423-37.
[22] O. JP, A.-L. B, H. AL, How many drug targets are there?, Nature reviews. Drug discovery 5(12) (2006) 993-6.
[23] E. RM, R. T, New insights into GPCR function: implications for HTS, Methods in molecular biology (Clifton, N.J.) 552 (2009) 1-13.
[24] V. A, S. A, B. V, M. B, The pros and cons of chemokines in tumor immunology, Trends in immunology 33(10) (2012) 496-504.
[25] L. B, S. M, M. LJ, W. D, D. RW, Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages, Proceedings of the National Academy of Sciences of the United States of America 96(9) (1999) 5215-20.
[26] H. M, K. E, M. A, R. JAK, L. SM, L. KR, M. H, K. M, T. LE, O. A, L. J, S. RC, S. S, G. J, I. KMS, D. I, S. S, W. W, A. B, L. J, D. B, A. S, I. M, G. M, L. J, C. K, F. MS, W. B, W. J, S. S, A. DO, P. S, V. V, S. D, W. KK, C. LM, M. G, Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming, Cancer discovery 9(9) (2019) 1288-1305.
[27] S. Y, U. S, K. M, S. T, T. JE, A. J, S. Y, K. M, K. K, M. N, M. K, Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice, Blood 111(12) (2008) 5457-66.
[28] S. Q, S. J, Z. C, C. J, Z. L, W. X, Transcription factor RUNX3 promotes CD8 T cell recruitment by CCL3 and CCL20 in lung adenocarcinoma immune microenvironment, Journal of cellular biochemistry 121 (2020) 3208-3220.
[29] Anti-CCR5 Therapy Circumvents Immune Cell Exploitation by Tumors, Cancer discovery 6(6) (2016) 571.
[30] H. N, Z. I, B. A, K. C, K. F, S.-C. M, S. T, B. K, K. J, L. F, L. T, L.-M. C, U. A, K. M, W. J, S. M, B. MW, Z. L, H. T, B. A, K. C, L. S, S. C, G. N, F. CS, J. D, Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients, Cancer cell 29(4) (2016) 587-601.
[31] L. J, W. C, M. X, T. Y, W. C, F. Y, L. Y, High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFβ1, The Journal of pathology 247(4) (2019) 481-493.
[32] K. G, F. C, Y. M, Y. KC, Reduced RhoA expression enhances breast cancer metastasis with a concomitant increase in CCR5 and CXCR4 chemokines signaling, Scientific reports 9(1) (2019) 16351.
[33] v.D. HW, W. QP, B. DT, D. BK, O.C. BP, T. JP, S. JS, C-C chemokine receptor 5 on pulmonary fibrocytes facilitates migration and promotes metastasis via matrix metalloproteinase 9, The American journal of pathology 173(1) (2008) 253-64.
[34] B. AC, P. N, T. RL, S. M, G. LA, G. ME, S. JR, F. RA, P. CA, Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES, Oncogene 27(4) (2008) 557-64.
[35] v.D. HW, O.C. W, B. WJ, A. RM, T. JP, S. JS, C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis, Cancer research 65(8) (2005) 3374-9.
[36] Y. HM, P. KR, P. MH, K. DH, J. MR, K. JY, K. EC, Y. DY, H. SB, H. JT, PRDX6 promotes tumor development via the JAK2/STAT3 pathway in a urethane-induced lung tumor model, Free radical biology & medicine 80 (2015) 136-44.
[37] W. Y, L. YY, M. K, B. T, M. N, CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process, Journal of immunology (Baltimore, Md. : 1950) 181(9) (2008) 6384-93.
[38] S. MJ, G. C, A. VR, F. R, R. P, W. DE, D. CJ, N. I, E. B, W. M, R. K, S. A, M. V, P. N, M. AS, Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer, Oncotarget 7(51) (2016) 85437-85449.
[39] R. BJ, R. H, R. R, N. RJ, G. RP, C. CL, R. BJ, High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens, Journal of immunology (Baltimore, Md. : 1950) 155(10) (1995) 4838-43.
[40] C. SW, W. KS, R. JH, S. PS, L. P, K. SL, Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production, Journal of immunology (Baltimore, Md. : 1950) 157(10) (1996) 4602-8.
[41] R. BJ, Chemokines, Blood 90(3) (1997) 909-28.
[42] v.D. HW, P. DA, W. QP, M. EC, S. JS, Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2, Journal of immunology (Baltimore, Md. : 1950) 190(9) (2013) 4861-7.
[43] E. T, W. K, J. J, M. C, Y. T, K. S, M.-E. J, L. T, F. M, R. F, H. M, W. XW, Z. L, G. TF, Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression, Cancer cell 30(4) (2016) 533-547.
[44] F. EF, K. EJ, B. EC, Integrating conflicting chemotactic signals. The role of memory in leukocyte navigation, The Journal of cell biology 147(3) (1999) 577-88.
[45] F. EF, C. JJ, B. EC, Multistep navigation and the combinatorial control of leukocyte chemotaxis, The Journal of cell biology 139(5) (1997) 1349-60.
[46] N. N, W. MS, Z. W, Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy, Nature reviews. Immunology 17(9) (2017) 559-572.
[47] B. F, Cancer and the chemokine network, Nature reviews. Cancer 4(7) (2004) 540-50.
[48] Z. M, X. W, W. C, H. J, X. J, Z. Y, Z. Y, C. J, D. S, L. B, L. C, CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis, Cell death & disease 10(11) (2019) 796.
[49] L. Q, S. L, G. B, Y. W, W. J, Z. D, H. X, Y. Z, S. Y, Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14, Cancer research 71(21) (2011) 6899-908.
[50] C. Y, L. Y, H. L, H. H, C. X, X. Y, Z. Z, C. J, C-C motif chemokine 14 as a novel potential biomarker for predicting the prognosis of epithelial ovarian cancer, Oncology letters 19(4) (2020) 2875-2883.
[51] L. Y, Z. Y, L. T, W. Q, Q. J, L. Y, Z. M, B. E, Y. M, R. F, Y. Q, C. Z, Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma, Oncotarget 6(27) (2015) 24218-29.
[52] S. AV, A. A, B. CY, K. AJ, S. S, R. TW, Hypothalamic neurohormones regulating anterior pituitary function, Recent progress in hormone research 24 (1968) 497-588.
[53] S. AV, A. A, K. AJ, M. H, B. Y, R. TW, N. RM, D. L, W. WF, Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones, Science (New York, N.Y.) 173(4001) (1971) 1036-8.
[54] K. S, Evolution of the regulatory mechanisms for the hypothalamic-pituitary-gonadal axis in vertebrates-hypothesis from a comparative view, General and comparative endocrinology 284 (2019).
[55] M. RP, L. ZL, P. AJ, F. CA, M. K, M. SR, Gonadotropin-releasing hormone receptors, Endocrine reviews 25(2) (2004) 235-75.
[56] F. RD, W. RB, Gonadotropin-releasing hormone genes: phylogeny, structure, and functions, Frontiers in neuroendocrinology 20(3) (1999) 224-40.
[57] N. JD, D. LW, S. JC, M. LC, K. JH, A regulator of G protein signaling, RGS3, inhibits gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone (LH) secretion, BMC cell biology 2 (2001) 21.
[58] M. R, L. S, C. D, P. A, M. S, T. B, O. T, M. M, L. G, S. R, F. B, S. G, K. R, T. E, K. A, A novel mammalian receptor for the evolutionarily conserved type II GnRH, Proceedings of the National Academy of Sciences of the United States of America 98(17) (2001) 9636-41.
[59] D. S, S. J, K. MM, R. CN, L. HY, G. VJ, Expression of GnRH type II is regulated by the androgen receptor in prostate cancer, Endocrine-related cancer 14(3) (2007) 613-24.
[60] P. S, H. JM, C. J, H. JI, S. JY, Apoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist, PloS one 9(6) (2014) e99723.
[61] L. P, M. RM, M.M. M, M. M, The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans, Frontiers in neuroendocrinology 24(4) (2003) 279-95.
[62] G. C, E. G, Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer, Reproductive biology and endocrinology : RB&E 1 (2003) 65.
[63] D. AT, C. RA, M. GA, F. JJ, L. CA, W. BR, LH-Independent Testosterone Secretion Is Mediated by the Interaction Between GNRH2 and Its Receptor Within Porcine Testes, Biology of reproduction 93(2) (2015) 45.
[64] C. KC, A. N, L. PC, Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells, The Journal of clinical endocrinology and metabolism 86(10) (2001) 5075-8.
[65] G. C, G. AR, M. RP, E. G, Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation, The Journal of clinical endocrinology and metabolism 87(3) (2002) 1427-30.
[66] C. A, K. E, R. S, B.-A. N, O. E, K. Y, Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breast tissue and overexpressed in breast cancer: a putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2, Cancer research 62(4) (2002) 1036-44.
[67] S. J, W. T, v.R. S, M. DH, G. L, S.-E. M, C. WT, C. BS, K. AM, B. XO, Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nature cell biology 10(12) (2008) 1470-6.
[68] H. IS, K. C, C. AP, L. PC, Gonadotropin-releasing hormone-I or -II interacts with IGF-I/Akt but not connexin 43 in human granulosa cell apoptosis, The Journal of clinical endocrinology and metabolism 97(2) (2012) 525-34.
[69] K. DK, Y. JS, M. K, H. JI, K. K, S. D, A. Y, L. C, K. BC, K. HB, C. J, S. JY, A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells, Cancer research 69(3) (2009) 923-31.
[70] E. N, G. AR, E. G, G. C, GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells, International journal of oncology 29(5) (2006) 1223-9.
[71] V. TH, W. Z, Matrix metalloproteinases: effectors of development and normal physiology, Genes & development 14(17) (2000) 2123-33.
[72] S. M, F. N, T. A, K. E, D. T, I. J, T. K, Y. A, K. S, U. T, E. M, The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer, The Journal of urology 199(3) (2018) 734-740.